Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?

about

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?

Item

http://www.wikidata.org/entity/Q39857880

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@en

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@nl

type

Item

label

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@en

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@nl

prefLabel

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@en

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@nl

P1476

Dihydropyrimidine dehydrogenas ...... neck cancers: Myth or reality?

@en

P2093

Amit Joshi

http://www.w3.org/2001/XMLSchema#string

Anant Ramaswamy

http://www.w3.org/2001/XMLSchema#string

Atanu Bhattacharjee

http://www.w3.org/2001/XMLSchema#string

Kumar Prabhash

http://www.w3.org/2001/XMLSchema#string

Saurabh Zanwar

http://www.w3.org/2001/XMLSchema#string

Supreeta Arya

http://www.w3.org/2001/XMLSchema#string

Vanita Noronha

http://www.w3.org/2001/XMLSchema#string

Vijay M Patil

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.

Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients - Single institute experience.

Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations.

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.

DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.

Biomarkers for personalized oncology: recent advances and future challenges.

P304

182-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2278-330X.195338

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Abhishek Mahajan

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28032083

http://www.w3.org/2001/XMLSchema#string

P932

5184753

http://www.w3.org/2001/XMLSchema#string